In Follow-up
Bladder
In Follow-up
BCG+MM
ANZUP 1301
NSW | VIC | QLD | WA | UK
Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: a randomised phase III trial
Prostate
In Follow-up
DASL-HiCaP
ANZUP 1801
NSW | VIC | QLD | SA | TAS | WA | NZ | Ireland | Canada | USA
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
Prostate
In Follow-up
ENZA-p
ANZUP 1901
NSW | VIC | QLD | SA | WA
A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in people with metastatic castration-resistant prostate cancer treated with enzalutamide.
Prostate
In Follow-up
ENZAMET
ANZUP 1304
NSW | VIC | QLD | NT | SA | TAS | WA | NZ | UK | Ireland | Canada | USA
Enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: a randomised phase III trial
Prostate
In Follow-up
ENZARAD
ANZUP 1303
NSW | VIC | QLD | SA | TAS | WA | NZ | UK | Ireland | Belgium | USA | Spain | Austria | Slovenia
Enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: a randomised phase III trial
Prostate
In Follow-up
EVOLUTION
ANZUP 2001
NSW | VIC | SA | WA
Phase II Study of Radionuclide 177Lu-PSMA Therapy versus 177Lu-PSMA in Combination with Ipilimumab and Nivolumab for people with Metastatic Castration Resistant Prostate Cancer
Kidney
In Follow-up
KEYPAD
ANZUP 1601
NSW | VIC | QLD | SA | WA
Denosumab and Pembrolizumab in clear cell renal carcinoma: a phase II trial
Bladder
In Follow-up
PCR MIB
ANZUP 1502
NSW | VIC | WA
Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
Prostate
In Follow-up
proPSMA
HREC/16/PMCC/130
NSW | VIC | QLD | SA | WA
A prospective randomised multi-centre study of the impact of Ga-68 PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy
Kidney
In Follow-up
RAMPART
ANZUP 1606
NSW | VIC | QLD | SA
Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi arm multi stage multi-centre randomised cont…
Prostate
In Follow-up
TheraP
ANZUP 1603
NSW | VIC | QLD | SA | WA
A randomised phase II trial of 177Lu-PSMA617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer
Testicular
In Follow-up
TIGER
ANZUP 1604
NSW | VIC | QLD | International
A Randomised Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Us…
Kidney
In Follow-up
UNICAB
ANZUP 1802
NSW | VIC | QLD | SA
A Phase II Trial Of Single Agent Cabozantinib In Patients With Locally Advanced Or Metastatic Non-Clear Cell Renal Cell Carcinoma Post Immunotherapy Or Who Are Unsuitable For Immunotherapy
Kidney
In Follow-up
UNISoN
ANZUP 1602
NSW | VIC | QLD | SA | WA
UNISoN: anzUp Nivo -> Ipi + Nivo Sequential Non-clear cell Proposed phase II sequential cohort trial of single agent Nivolumab, then combination Ipil…
Prostate
In Follow-up
#UpFrontPSMA
18/047
NSW | VIC | QLD | SA | WA
A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer
Kidney
In Follow-up
FASTRACK II
TROG 15.03
NSW | VIC | QLD | SA
TROG 15.03 Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney – A Phase II Clinical Trial
Bladder
In Follow-up
NMIBC-SI Evaluation
N/A
NSW | VIC | QLD | WA | NZ | UK | Canada | USA
Developing a Patient-Reported Symptom Index for Non-muscle Invasive Bladder Cancer